文献速递肿瘤 PET/CT核素与放射性配体治疗

18F-FDG PET/CT 相比 68Ga-PSMA PET/CT 在去势抵抗性前列腺癌患者中的附加价值

The Added Value of 18F-FDG PET/CT Compared with 68Ga-PSMA PET/CT in Patients with Castration-Resistant Prostate Cancer.
PubMed 文献 · J Nucl Med · 2022-01-01

该回顾性研究分析56例去势抵抗性前列腺癌(CRPC)患者,比较68Ga-PSMA与18F-FDG PET/CT的诊断效能。68Ga-PSMA PET/CT检出率和阳性病灶数更高(75.0% vs 51.8%,P=0.004;135 vs 95),但仍有13/56(23.2%)患者存在68Ga-PSMA阴性、18F-FDG阳性病灶。Gleason评分≥8和PSA≥7.9 ng/mL是此类病灶的预测因素,高概率组发生率61.5%。

要点

  • 68Ga-PSMA PET/CT检出率75.0%高于18F-FDG的51.8%(P=0.004),阳性病灶数135 vs 95。
  • 23.2%(13/56)CRPC患者存在至少1个68Ga-PSMA阴性、18F-FDG阳性病灶。
  • Gleason评分≥8和PSA≥7.9 ng/mL是68Ga-PSMA阴性、18F-FDG阳性病灶的预测因素。

核心结论

  • Gleason评分和PSA是68Ga-PSMA阴性、18F-FDG阳性病灶的显著预测因素,Gleason评分和PSA高的CRPC患者可能从额外18F-FDG PET/CT中获益。

研究设计与样本

  • 回顾性分析2018年5月至2021年2月间同时接受68Ga-PSMA和18F-FDG PET/CT的56例CRPC患者数据。
  • 患者分为有或无68Ga-PSMA阴性、18F-FDG阳性病灶两组,分析两组患者特征差异及至少1个此类病灶的预测因素。

主要发现

  • 68Ga-PSMA PET/CT检出率75.0% vs 18F-FDG PET/CT 51.8%(P=0.004),阳性病灶数135 vs 95。
  • 13/56(23.2%)患者存在至少1个68Ga-PSMA阴性、18F-FDG阳性病灶。
  • 有68Ga-PSMA阴性、18F-FDG阳性病灶的患者PSA和Gleason评分均高于无此类病灶者(P=0.04和P<0.001)。
  • 多因素回归分析显示Gleason评分(≥8)和PSA(≥7.9 ng/mL)与68Ga-PSMA阴性、18F-FDG阳性病灶检出率相关(P=0.01和P=0.04)。
  • 低概率组(Gleason评分<8且PSA<7.9 ng/mL)、中概率组(Gleason评分≥8且PSA<7.9 ng/mL或Gleason评分<8且PSA≥7.9 ng/mL)、高概率组(Gleason评分≥8且PSA≥7.9 ng/mL)的发生率分别为0%、21.7%、61.5%(P<0.001)。

临床怎么用

  • 作者认为Gleason评分和PSA高的CRPC患者可能从额外18F-FDG PET/CT中获益。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

68Ga-prostate-specific membrane antigen (68Ga-PSMA) PET/CT is a commonly used imaging modality in prostate cancers. However, few studies have compared the diagnostic efficiency between 68Ga-PSMA and 18F-FDG PET/CT and evaluated whether a heterogeneous metabolic phenotype (especially 68Ga-PSMA-negative [-], 18F-FDG-positive [+] lesions) exists in patients with castration-resistant prostate cancer (CRPC). We determined the added value of 18F-FDG PET/CT compared with 68Ga-PSMA PET/CT in CRPC patients and identified CRPC patients who may benefit from additional 18F-FDG PET/CT. Methods: The data of 56 patients with CRPC who underwent both 68Ga-PSMA and 18F-FDG PET/CT from May 2018 to February 2021 were retrospectively analyzed. The patients were classified into 2 groups: with or without 68Ga-PSMA-, 18F-FDG+ lesions. The differences in patient characteristics between the 2 groups and predictors of patients who have at least 1 68Ga-PSMA-, 18F-FDG+ lesion were analyzed. Results: Although both the detection rate (75.0% vs. 51.8%, P = 0.004) and the number of positive lesions (135 vs. 95) were higher for 68Ga-PSMA PET/CT than for 18F-FDG PET/CT, there were still 13 of 56 (23.2%) patients with at least 1 68Ga-PSMA-, 18F-FDG+ lesion. Prostate-specific antigen (PSA) and the Gleason score were both higher in patients with 68Ga-PSMA-, 18F-FDG+ lesions than in those without (P = 0.04 and P < 0.001, respectively). Multivariate regression analysis showed that the Gleason score (≥8) and PSA (≥7.9 ng/mL) were associated with the detection rate of patients who had 68Ga-PSMA-, 18F-FDG+ lesions (P = 0.01 and P = 0.04, respectively). The incidences of having 68Ga-PSMA-, 18F-FDG+ lesions in low-probability (Gleason score < 8 and PSA < 7.9 ng/mL), medium-probability (Gleason score ≥ 8 and PSA < 7.9 ng/mL or Gleason score < 8 and PSA ≥ 7.9 ng/mL), and high-probability (Gleason score ≥ 8 and PSA ≥ 7.9 ng/mL) groups were 0%, 21.7%, and 61.5%, respectively (P < 0.001). Conclusion: Gleason score and PSA are significant predictors of 68Ga-PSMA-, 18F-FDG+ lesions, and CRPC patients with a high Gleason score and PSA may benefit from additional 18F-FDG PET/CT.

来源:J Nucl Med,查看原文。版权归原作者所有。

引用

  1. Chen R, Wang Y, Zhu Y, et al. The Added Value of 18F-FDG PET/CT Compared with 68Ga-PSMA PET/CT in Patients with Castration-Resistant Prostate Cancer. J Nucl Med. 2022. PMID: 34980667. doi:10.2967/jnumed.120.262250

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。